Gut Microbiome and Associated Systemic Inflammation Regulates Trafficking of Engineered Nanovaccines

摘要

Conclusion: Here we demonstrate that polymeric nanoparticle vaccines can have varied distribution in body as a function of gut associated systemic inflammation, which previously has not been adequately considered in vaccination studies. This work has the potential to provide the first evidence that changes in gut flora (the upstream cause of the TLR5-/- phenotype) can influence vaccine's interaction with antigen presenting cells and resulting B and T cell adaptive immunity by altering local and systemic inflammation. Our ability to better understand how biomaterials-based pathogen-mimicking micro and nanoparticle vaccines trigger and control mammalian immunity across various demographics, will greatly help the design and clinical translation of more effective vaccines against emerging infectious diseases, HIV/AIDS, cancer, etc.